Kapidex, available in 30mg and 60mg doses, was recently approved by the FDA for the treatment of heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD), the healing of erosive esophagitis (EE) and the maintenance of healed EE.
According to the company, Kapidex is the first proton pump inhibitor (PPI) with a dual delayed release formulation designed to provide two separate releases of medication. PPIs work by turning off many of the acid pumps in the stomach.
Kapidex contains two types of enteric-coated granules resulting in a concentration-time profile with two distinct peaks: the first peak occurs one to two hours after administration, followed by a second peak within four to five hours. In addition, Kapidex can be taken regardless of when food is consumed, the company said.